Regression of established B16F10 melanoma with a recombinant Listeria monocytogenes vaccine.
We have previously shown that Listeria monocytogenes, a gram-positive, facultative intracellular bacterium, is a potent vector for targeting tumor-specific antigens to the immune system. In the present study, we extend these studies to the highly tumorigenic mouse melanoma B16F10, transduced with a model tumor antigen. We are able to induce the regression of primary tumors and established lung metastases by parenteral immunization with a L. monocytogenes recombinant that expresses the same antigen. Adjunctive therapy with granulocyte macrophage colony-stimulating factor or a vaccinia-based vaccine does not result in an improved cure rate over the L. monocytogenes vaccine alone. Tumor regression is accompanied by the expression of inflammatory cytokines in the tumor.
Pan
Z K
ZK
Department of Microbiology and the University of Pennsylvania Cancer Center, University of Pennsylvania, Philadelphia 19104-6076, USA.
Weiskirch
L M
LM
Paterson
Y
Y
D000818:Animals; D001428:Bacterial Vaccines / Q000627:therapeutic use*; D016207:Cytokines / Q000235:genetics; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000378:metabolism; D008089:Listeria monocytogenes / Q000276:immunology*; D008175:Lung Neoplasms / Q000517:prevention & control / Q000556:secondary; D008546:Melanoma, Experimental / Q000628:therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D012333:RNA, Messenger / Q000032:analysis; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000627:therapeutic use*; D014616:Vaccinia virus / Q000276:immunology; D014765:Viral Vaccines / Q000627:therapeutic use
D001428:Bacterial Vaccines; D016207:Cytokines; D012333:RNA, Messenger; D014614:Vaccines, Synthetic; D014765:Viral Vaccines; D016178:Granulocyte-Macrophage Colony-Stimulating Factor